ClariVest Asset Management LLC Grows Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)

ClariVest Asset Management LLC grew its stake in shares of Denali Therapeutics Inc. (NASDAQ:DNLI) by 18.8% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 47,748 shares of the company’s stock after acquiring an additional 7,568 shares during the quarter. ClariVest Asset Management LLC’s holdings in Denali Therapeutics were worth $980,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. PNC Financial Services Group Inc. increased its stake in shares of Denali Therapeutics by 48.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 2,486 shares of the company’s stock valued at $53,000 after acquiring an additional 807 shares during the last quarter. CWM LLC increased its position in Denali Therapeutics by 216.7% during the 4th quarter. CWM LLC now owns 2,011 shares of the company’s stock worth $43,000 after purchasing an additional 1,376 shares in the last quarter. Assetmark Inc. increased its position in Denali Therapeutics by 65.3% during the 4th quarter. Assetmark Inc. now owns 3,550 shares of the company’s stock worth $76,000 after purchasing an additional 1,402 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Denali Therapeutics by 10.2% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 22,787 shares of the company’s stock worth $489,000 after purchasing an additional 2,108 shares in the last quarter. Finally, Fisher Asset Management LLC acquired a new stake in Denali Therapeutics during the 4th quarter worth approximately $59,000. Institutional investors and hedge funds own 92.92% of the company’s stock.

Insider Activity

In other Denali Therapeutics news, Director Steve E. Krognes sold 30,000 shares of the business’s stock in a transaction on Monday, July 1st. The stock was sold at an average price of $22.12, for a total value of $663,600.00. Following the transaction, the director now owns 34,404 shares of the company’s stock, valued at $761,016.48. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. In other Denali Therapeutics news, Director Vicki L. Sato sold 1,666 shares of the stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $18.29, for a total value of $30,471.14. Following the completion of the sale, the director now directly owns 118,043 shares in the company, valued at $2,159,006.47. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Steve E. Krognes sold 30,000 shares of the stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $22.12, for a total value of $663,600.00. Following the completion of the sale, the director now owns 34,404 shares of the company’s stock, valued at $761,016.48. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 33,812 shares of company stock worth $740,745. Company insiders own 7.90% of the company’s stock.

Denali Therapeutics Trading Down 1.0 %

NASDAQ DNLI traded down $0.23 during trading on Friday, reaching $22.86. 735,710 shares of the company’s stock were exchanged, compared to its average volume of 1,301,758. Denali Therapeutics Inc. has a fifty-two week low of $14.56 and a fifty-two week high of $30.79. The firm has a market capitalization of $3.26 billion, a PE ratio of -23.81 and a beta of 1.40. The company’s fifty day simple moving average is $20.62 and its 200-day simple moving average is $19.27.

Denali Therapeutics (NASDAQ:DNLI) last issued its quarterly earnings results on Tuesday, May 7th. The company reported ($0.68) EPS for the quarter, topping the consensus estimate of ($0.69) by $0.01. During the same period in the prior year, the company earned ($0.80) earnings per share. Equities analysts forecast that Denali Therapeutics Inc. will post -2.78 EPS for the current fiscal year.

Analyst Ratings Changes

DNLI has been the subject of a number of research analyst reports. UBS Group dropped their target price on shares of Denali Therapeutics from $70.00 to $32.00 and set a “buy” rating for the company in a research report on Tuesday, April 9th. HC Wainwright reissued a “buy” rating and set a $95.00 target price on shares of Denali Therapeutics in a research report on Wednesday, May 8th. Wedbush dropped their target price on shares of Denali Therapeutics from $31.00 to $30.00 and set an “outperform” rating for the company in a research report on Wednesday, May 8th. Stifel Nicolaus lowered their price objective on shares of Denali Therapeutics from $26.00 to $22.00 and set a “hold” rating for the company in a research report on Wednesday, May 8th. Finally, JPMorgan Chase & Co. increased their price objective on shares of Denali Therapeutics from $28.00 to $29.00 and gave the company an “overweight” rating in a research report on Wednesday. One analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $40.33.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.